View live charts, options flow & technicals for NovoCure Limited →
Open Dashboard
NovoCure Limited (NVCR) is a healthcare company in the medical devices industry with $700.00M in trailing revenue — analyst consensus: none.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Key Statistics
Market Cap
$1.84B
Revenue (TTM)
$700.00M
EPS (TTM)
$-1.30
EPS (Fwd est.)
$-0.82
Employees
1,605
Forward P/E
-19.40
Price / Sales
2.64
Price / Book
5.45
EV / EBITDA
-12.01
Beta (5Y)
1.01
Analyst Consensus
Consensus
None
Analyst Price Target
+71.4% upside
Target: $27.14
Annual Revenue & Net Income
RevenueNet Income
'22
$540.00M
$-90.00M
'23
$510.00M
$-210.00M
'24
$610.00M
$-170.00M
'25
$660.00M
$-140.00M
Earnings History
Quarter
Actual EPS
Estimate
Result
Jul 2026
$-0.13
$-0.33
Beat (+60.8%)
Apr 2026
$-0.62
$-0.51
Miss (-20.9%)
Feb 2026
$-0.22
$-0.41
Beat (+46.5%)
Oct 2025
$-0.33
$-0.42
Beat (+21.4%)
Next Earnings Report
NovoCure Limited is next expected to report earnings on 29 Oct 2026.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTF…
What is NVCR's market cap?
NovoCure Limited has a market capitalization of approximately $1.84B.
How much revenue does NVCR generate?
NovoCure Limited generated $700.00M in trailing 12-month revenue.
What do analysts say about NVCR?
The analyst consensus rating for NovoCure Limited is none, with a mean price target of $27.14. That implies +71.4% upside from the current price.
When does NVCR report earnings?
NovoCure Limited is next scheduled to report earnings on 29 Oct 2026.
Does NVCR pay a dividend?
NovoCure Limited does not currently pay a regular dividend.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for NovoCure Limited on Apsis Markets.
